Miroslav Sokolov’s Post

Early treatment of chronic kidney disease (CKD) can slow or halt its progression, improve quality of life, and reduce cardiovascular risk. Sadly, 90% of patients with CKD are undiagnosed. During UNGA79, AstraZeneca — together with co-sponsor Boehringer Ingelheim and partners the International Society of Nephrology Global Patient Alliance for Kidney Health, and co-host Devex — convened leading voices in global health and policy for a critical discussion on the urgent need to implement patient-centred and evidence-based policies to enable earlier detection and diagnosis of CKD and immediate access to care and recommended treatments. We need to act now. Sign up to be part of making the change: https://lnkd.in/eyhQg79y #UNGA79 #ForKidneyHealth https://lnkd.in/ejXEG-JU

Early treatment of chronic kidney disease (CKD) can slow or halt its progression, improve quality of life, and reduce cardiovascular risk. Sadly, 90% of patients with CKD are undiagnosed. During UNGA79, AstraZeneca — together with co-sponsor Boehringer Ingelheim and partners the International Society of Nephrology Global Patient Alliance for Kidney Health, and co-host Devex — convened leading voices in global health and policy for a critical discussion on the urgent need to implement patient-centred and evidence-based policies to enable earlier detection and diagnosis of CKD and immediate access to care and recommended treatments. We need to act now. Sign up to be part of making the change: https://lnkd.in/egvUZA4y #UNGA79 #ForKidneyHealth https://lnkd.in/eNi6DBQZ

Early treatment of chronic kidney disease (CKD) can slow or halt its progression, improve quality of life, and reduce cardiovascular risk. Sadly, 90% of patients with CKD are undiagnosed. During UNGA79, AstraZeneca — together with co-sponsor Boehringer Ingelheim and partners the International Society of Nephrology Global Patient Alliance for Kidney Health, and co-host Devex — convened leading voices in global health and policy for a critical discussion on the urgent need to implement patient-centred and evidence-based policies to enable earlier detection and diagnosis of CKD and immediate access to care and recommended treatments. We need to act now. Sign up to be part of making the change: https://lnkd.in/ewpy5TCe #UNGA79 #ForKidneyHealth https://lnkd.in/e5SV4RHt

Early treatment of chronic kidney disease (CKD) can slow or halt its progression, improve quality of life, and reduce cardiovascular risk. Sadly, 90% of patients with CKD are undiagnosed. During UNGA79, AstraZeneca — together with co-sponsor Boehringer Ingelheim and partners the International Society of Nephrology Global Patient Alliance for Kidney Health, and co-host Devex — convened leading voices in global health and policy for a critical discussion on the urgent need to implement patient-centred and evidence-based policies to enable earlier detection and diagnosis of CKD and immediate access to care and recommended treatments. We need to act now. Sign up to be part of making the change: https://lnkd.in/eXFe-UJf #UNGA79 #ForKidneyHealth https://lnkd.in/ePHbvkvt

Early treatment of chronic kidney disease (CKD) can slow or halt its progression, improve quality of life, and reduce cardiovascular risk. Sadly, 90% of patients with CKD are undiagnosed. During UNGA79, AstraZeneca — together with co-sponsor Boehringer Ingelheim and partners the International Society of Nephrology Global Patient Alliance for Kidney Health and co-host Devex — convened leading voices in global health and policy for a critical discussion on the urgent need to implement patient-centred and evidence-based policies to enable earlier detection and diagnosis of CKD and immediate access to care and recommended treatments. We need to act now. Sign up to be part of making the change: https://lnkd.in/gi5SZkUt #UNGA79 #ForKidneyHealth https://lnkd.in/gXsnmQEu

Early treatment of chronic kidney disease (CKD) can slow or halt its progression, improve quality of life, and reduce cardiovascular risk. Sadly, 90% of patients with CKD are undiagnosed. During UNGA79, AstraZeneca — together with co-sponsor Boehringer Ingelheim and partners the International Society of Nephrology Global Patient Alliance for Kidney Health, and co-host Devex — convened leading voices in global health and policy for a critical discussion on the urgent need to implement patient-centred and evidence-based policies to enable earlier detection and diagnosis of CKD and immediate access to care and recommended treatments. We need to act now. Sign up to be part of making the change: https://lnkd.in/g7MWSBE8 #UNGA79 #ForKidneyHealth https://lnkd.in/gjw8i25E

Early treatment of chronic kidney disease (CKD) can slow or halt its progression, improve quality of life, and reduce cardiovascular risk. Sadly, 90% of patients with CKD are undiagnosed. During UNGA79, AstraZeneca — together with co-sponsor Boehringer Ingelheim and partners the International Society of Nephrology Global Patient Alliance for Kidney Health and co-host Devex — convened leading voices in global health and policy for a critical discussion on the urgent need to implement patient-centred and evidence-based policies to enable earlier detection and diagnosis of CKD and immediate access to care and recommended treatments. We need to act now. Sign up to be part of making the change: https://lnkd.in/eG25KY8E #UNGA79 #ForKidneyHealth https://lnkd.in/eM2yBFFp

Early treatment of chronic kidney disease (CKD) can slow or halt its progression, improve quality of life, and reduce cardiovascular risk. Sadly, 90% of patients with CKD are undiagnosed. During UNGA79, AstraZeneca — together with co-sponsor Boehringer Ingelheim and partners the International Society of Nephrology Global Patient Alliance for Kidney Health and co-host Devex — convened leading voices in global health and policy for a critical discussion on the urgent need to implement patient-centred and evidence-based policies to enable earlier detection and diagnosis of CKD and immediate access to care and recommended treatments. We need to act now. Sign up to be part of making the change: https://lnkd.in/e6FPqg4t #UNGA79 #ForKidneyHealth https://lnkd.in/eJGTj8Yy

Hypertrophic cardiomyopathy (HCM) emerged as a distinct disease about 60 years ago, yet the condition is still often underdiagnosed and inconsistently managed, leading to delayed treatment, increased risk of complications and preventable morbidity. While rare, HCM is the most common inherited heart disease, and it is estimated that 1 in 500 people are living with HCM and are unaware. The American Heart Association is thrilled to announce a groundbreaking $8M Hypertrophic Cardiomyopathy Registry, Recognition, and Site Certification Initiative to establish a comprehensive HCM system of care, anchored in evidence-based measures and quality thresholds. This three-year initiative aims to improve patient outcomes and care by standardizing the assessment, referral and treatment of patients with HCM. We extend our sincere gratitude to founding sponsor Bristol Myers Squibb for their support in helping translate science into practice. Learn more about this new initiative at http://spr.ly/6046spyvQ. #HCM #AHA24

The CardioHealth Alliance and partners Boehringer Ingelheim, Eli Lilly and Company and Bayer have announced IRIS-CKD, a new study that aims to improve diagnosis and treatment for chronic kidney disease in patients with Type 2 diabetes mellitus. #diabetes #CKD. Learn more about the study being led by the DCRI's Neha Pagidipati, and how it aims to improve patient information, access to care, and engagement: https://lnkd.in/eD6RAEkz #clinicaltrials #clinicalresearch #kidneydisease #diabetes